Haloperidol and clozapine decrease S100B release from glial cells

Neuroscience

Volumn 167, Issue 4, 2010, Pages 1025-1031

  Steiner, J ^a   Schroeter, M L ^b,c   Schiltz, K ^a   Bernstein, H G ^a   Muller U J ^a   Richter Landsberg, C ^d   Muller W E ^e   Walter, M ^a   Gos, T ^a,f   Bogerts, B ^a   Keilhoff, G ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF OLDENBURG   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Astrocytes; Clozapine; Haloperidol; Oligodendrocytes; S100B; Schizophrenia

Indexed keywords

CLOZAPINE; GLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; PROTEIN S100B;

ANIMAL CELL; ARTICLE; ASTROCYTE; BODY FLUID; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; ENERGY METABOLISM; GLIA CELL; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; CLOZAPINE; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; GLUCOSE; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; NERVE GROWTH FACTORS; NEUROGLIA; RATS; RECEPTORS, NEUROTRANSMITTER; S100 PROTEINS;

EID: 77952546328     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.03.010     Document Type: Article

References (46)

1. Akhisaroglu M., Manev R., Akhisaroglu E., Uz T., Manev H. Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. Neuroreport 2003, 14:1471-1473.
2. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993, 9:117-124.
3. Bernstein H.G., Steiner J., Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 2009, 9:1059-1071.
4. Dean B., Gray L., Scarr E. Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Aust N Z J Psychiatry 2006, 40:217-224.
5. Deloulme J.C., Raponi E., Gentil B.J., Bertacchi N., Marks A., Labourdette G., Baudier J. Nuclear expression of S100B in oligodendrocyte progenitor cells correlates with differentiation toward the oligodendroglial lineage and modulates oligodendrocytes maturation. Mol Cell Neurosci 2004, 27:453-465.
6. Eriksen J.L., Gillespie R., Druse M.J. Effects of ethanol and 5-HT1A agonists on astroglial S100B. Brain Res Dev Brain Res 2002, 139:97-105.
7. Gattaz W.F., Lara D.R., Elkis H., Portela L.V., Goncalves C.A., Tort A.B., Henna J., Souza D.O. Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr Res 2000, 43:91-95.
8. Gerlach R., Demel G., Konig H.G., Gross U., Prehn J.H., Raabe A., Seifert V., Kogel D. Active secretion of S100B from astrocytes during metabolic stress. Neuroscience 2006, 141:1697-1701.
9. Holmes E., Tsang T.M., Huang J.T., Leweke F.M., Koethe D., Gerth C.W., Nolden B.M., Gross S., Schreiber D., Nicholson J.K., Bahn S. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006, 3:e327.
10. Huang J.T., Leweke F.M., Tsang T.M., Koethe D., Kranaster L., Gerth C.W., Gross S., Schreiber D., Ruhrmann S., Schultze-Lutter F., Klosterkotter J., Holmes E., Bahn S. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2007, 2:e756.
11. Keilhoff G., Wolf G. Comparison of double fluorescence staining and LDH-test for monitoring cell viability in vitro. Neuroreport 1993, 5:129-132.
12. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zochling R., Boissl K.W., Leblhuber F., Riederer P. Persistence of haloperidol in human brain tissue. Am J Psychiatry 1999, 156:885-890.
13. Ling S.H., Tang Y.L., Jiang F., Wiste A., Guo S.S., Weng Y.Z., Yang T.S. Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 2007, 41:36-42.
14. Liu J., Shi Y., Tang J., Guo T., Li X., Yang Y., Chen Q., Zhao X., He G., Feng G., Gu N., Zhu S., Liu H., He L. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 2005, 328:335-341.
15. Liu Y., Buck D.C., Neve K.A. Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function. Mol Pharmacol 2008, 74:371-378.
16. Manev R., Uz T., Manev H. Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus. Eur J Pharmacol 2001, 420:R1-R2.
17. Nardin P., Tramontina F., Leite M.C., Tramontina A.C., Quincozes-Santos A., de Almeida L.M., Battastini A.M., Gottfried C., Goncalves C.A. S100B content and secretion decrease in astrocytes cultured in high-glucose medium. Neurochem Int 2007, 50:774-782.
18. Netto C.B., Conte S., Leite M.C., Pires C., Martins T.L., Vidal P., Benfato M.S., Giugliani R., Goncalves C.A. Serum S100B protein is increased in fasting rats. Arch Med Res 2006, 37:683-686.
19. Qi L.Y., Xiu M.H., Chen D.C., Wang F., Kosten T.A., Kosten T.R., Zhang X.Y. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett 2009, 462:113-117.
20. Quincozes-Santos A., Abib R.T., Leite M.C., Bobermin D., Bambini-Junior V., Goncalves C.A., Riesgo R., Gottfried C. Effect of the atypical neuroleptic risperidone on morphology and S100B secretion in C6 astroglial lineage cells. Mol Cell Biochem 2008, 314:59-63.
21. Raponi E., Agenes F., Delphin C., Assard N., Baudier J., Legraverend C., Deloulme J.C. S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. Glia 2007, 55:165-177.
22. Richter-Landsberg C., Heinrich M. OLN-93: a new permanent oligodendroglia cell line derived from primary rat brain glial cultures. J Neurosci Res 1996, 45:161-173.
23. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., Suslow T., Peters M., Kaestner F., Heindel W., Arolt V., Pfleiderer B. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:361-364.
24. Rothermundt M., Ponath G., Glaser T., Hetzel G., Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004, 29:1004-1011.
25. Schmitt A., Bertsch T., Henning U., Tost H., Klimke A., Henn F.A., Falkai P. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res 2005, 80:305-313.
26. Schroeter M.L., Abdul-Khaliq H., Fruhauf S., Hohne R., Schick G., Diefenbacher A., Blasig I.E. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 2003, 62:231-236.
27. Schroeter M.L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I.E. NSE is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res 2009, 167:66-72.
28. Schroeter M.L., Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009, 14:235-237.
29. Steiner J., Bernstein H.G., Bielau H., Berndt A., Brisch R., Mawrin C., Keilhoff G., Bogerts B. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007, 8:2.
30. Steiner J., Bernstein H.G., Bielau H., Farkas N., Winter J., Dobrowolny H., Brisch R., Gos T., Mawrin C., Myint A.M., Bogerts B. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 2008, 42:868-876.
31. Steiner J., Bernstein H.G., Bogerts B., Gos T., Richter-Landsberg C., Wunderlich M.T., Keilhoff G. S100B is expressed in, and released from, OLN-93 oligodendrocytes: influence of serum and glucose deprivation. Neuroscience 2008, 154:496-503.
32. Steiner J., Bielau H., Bernstein H.G., Bogerts B., Wunderlich M.T. Increased cerebrospinal fluid and serum levels of S100B in firstonset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006, 77:1284-1287.
33. Steiner J., Schiltz K., Walter M., Wunderlich M.T., Keilhoff G., Brisch R., Bielau H., Bernstein H.G., Bogerts B., Schroeter M.L., Westphal S. S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology 2010, 35:321-324.
34. Steiner J., Walter M., Guest P.C., Myint A.M., Schiltz K., Panteli B., Brauner M., Bernstein H.G., Gos T., Herberth M., Schroeter M.L., Schwarz M.J., Westphal S., Bahn S., Bogerts B. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 2010, 15:3-4.
35. Steiner J., Walter M., Wunderlich M.T., Bernstein H.G., Panteli B., Brauner M., Jacobs R., Gos T., Rothermundt M., Bogerts B. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 2009, 65:1107-1110.
36. Stone J.M., Morrison P.D., Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review. J Psychopharmacol 2007, 21:440-452.
37. Thakore J.H. Metabolic syndrome and schizophrenia. Br J Psychiatry 2005, 186:455-456.
38. Tiu S.C., Chan W.Y., Heizmann C.W., Schafer B.W., Shu S.Y., Yew D.T. Differential expression of S100B and S100A6 in the human fetal and aged cerebral cortex. Brain Res Dev Brain Res 2000, 119:159-168.
39. Tramontina A.C., Tramontina F., Bobermin L.D., Zanotto C., Souza D.F., Leite M.C., Nardin P., Gottfried C., Goncalves C.A. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1580-1583.
40. Tramontina F., Leite M.C., Goncalves D., Tramontina A.C., Souza D.F., Frizzo J.K., Nardin P., Gottfried C., Wofchuk S.T., Goncalves C.A. High glutamate decreases S100B secretion by a mechanism dependent on the glutamate transporter. Neurochem Res 2006, 31:815-820.
41. Tramontina F., Tramontina A.C., Souza D.F., Leite M.C., Gottfried C., Souza D.O., Wofchuk S.T., Goncalves C.A. Glutamate uptake is stimulated by extracellular S100B in hippocampal astrocytes. Cell Mol Neurobiol 2006, 26:81-86.
42. Weigmann H., Hartter S., Fischer V., Dahmen N., Hiemke C. Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur Neuropsychopharmacol 1999, 9:253-256.
43. Wiesmann M., Wandinger K.P., Missler U., Eckhoff D., Rothermundt M., Arolt V., Kirchner H. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 1999, 45:1508-1511.
44. Zhang G., Terry A.V., Bartlett M.G. Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 858:276-281.
45. Zhao Z., Ksiezak-Reding H., Riggio S., Haroutunian V., Pasinetti G.M. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 2006, 84:1-14.
46. Zimmer D.B., Chessher J., Wilson G.L., Zimmer W.E. S100A1 and S100B expression and target proteins in type I diabetes. Endocrinology 1997, 138:5176-5183.